Contact
searchSearch
HMP Global
Login

Mantle Cell Lymphoma

News
Study Shows Improved Outcomes in Older Adults With Mantle Cell Lymphoma Following Adoption of New Therapies
06/16/2025
Juliet Gallagher
New findings from a large, retrospective cohort study using SEER-Medicare data highlight improvements in survival outcomes over time among older adults with mantle cell lymphoma (MCL), likely associated with the adoption of novel therapeutic...
New findings from a large, retrospective cohort study using SEER-Medicare data highlight improvements in survival outcomes over time among older adults with mantle cell lymphoma (MCL), likely associated with the adoption of novel therapeutic...
New findings from a large,...
06/16/2025
Journal of Clinical Pathways
News
Ibrutinib Plus Venetoclax Improves Outcomes in Relapsed Mantle Cell Lymphoma: SYMPATICO Trial
06/11/2025
Grace Taylor, MS, MA
Findings from the SYMPATICO trial show that combining ibrutinib with venetoclax significantly prolongs progression-free survival in relapsed mantle cell lymphoma.
Findings from the SYMPATICO trial show that combining ibrutinib with venetoclax significantly prolongs progression-free survival in relapsed mantle cell lymphoma.
Findings from the SYMPATICO...
06/11/2025
Journal of Clinical Pathways
News
Safety and Tolerability of Second Generation BTK Inhibitors in Relapsed Mantle Cell Lymphoma
05/14/2025
Grace Taylor, MS, MA
Real-world findings support the tolerability of acalabrutinib and zanubrutinib in mantle cell lymphoma, highlighting their safety advantage over ibrutinib.
Real-world findings support the tolerability of acalabrutinib and zanubrutinib in mantle cell lymphoma, highlighting their safety advantage over ibrutinib.
Real-world findings support the...
05/14/2025
Journal of Clinical Pathways
News
Study Shows Promising Safety and Efficacy of ABR Combination in Mantle Cell Lymphoma
05/07/2025
Grace Taylor, MS, MA
The combination therapy of acalabrutinib, bendamustine, and rituximab shows promise in a recent study for mantle cell lymphoma.
The combination therapy of acalabrutinib, bendamustine, and rituximab shows promise in a recent study for mantle cell lymphoma.
The combination therapy of...
05/07/2025
Journal of Clinical Pathways
News
New Risk Model Enhances Prognostic Precision in Mantle Cell Lymphoma
04/10/2025
Danielle Sposato
A large retrospective study published in Scientific Reports involving 979 patients from 9 cancer centers has introduced a powerful new prognostic tool for mantle cell lymphoma (MCL), a rare and aggressive form of non-Hodgkin lymphoma.
A large retrospective study published in Scientific Reports involving 979 patients from 9 cancer centers has introduced a powerful new prognostic tool for mantle cell lymphoma (MCL), a rare and aggressive form of non-Hodgkin lymphoma.
A large retrospective study...
04/10/2025
Journal of Clinical Pathways
News
Survival in Mantle Cell Lymphoma Improves With Shifts in Treatment Patterns
04/07/2025
Hannah Musick
A study of older MCL patients found significant survival gains linked to increased first-line use of rituximab-bendamustine (BR) and Bruton tyrosine kinase inhibitors (BTKis), but more modest improvements after second-line therapy.
A study of older MCL patients found significant survival gains linked to increased first-line use of rituximab-bendamustine (BR) and Bruton tyrosine kinase inhibitors (BTKis), but more modest improvements after second-line therapy.
A study of older MCL patients...
04/07/2025
Journal of Clinical Pathways
News
Academic Cancer Centers Improve Outcomes for Patients With Mantle Cell Lymphoma
03/18/2025
Lisa Kuhns, PhD, MD
Patients with mantle cell lymphoma (MCL) who receive treatment at academic cancer centers experience longer overall survival and higher participation in clinical trials compared to those treated in community-based practices, according to a...
Patients with mantle cell lymphoma (MCL) who receive treatment at academic cancer centers experience longer overall survival and higher participation in clinical trials compared to those treated in community-based practices, according to a...
Patients with mantle cell...
03/18/2025
Journal of Clinical Pathways
News
Early Measurable Residual Disease Assessment Predicts Survival in Patients With Mantle Cell Lymphoma
03/12/2025
Lisa Kuhns, PhD, MD
Patients with mantle cell lymphoma (MCL) can benefit from measurable residual disease (MRD) assessment during induction therapy, with the timing and kinetics of MRD negativity significantly impacting prognosis and treatment strategies,...
Patients with mantle cell lymphoma (MCL) can benefit from measurable residual disease (MRD) assessment during induction therapy, with the timing and kinetics of MRD negativity significantly impacting prognosis and treatment strategies,...
Patients with mantle cell...
03/12/2025
Journal of Clinical Pathways
News
CAR T-Cell Therapy Cuts Costs and Improves Treatment-Free Intervals
03/04/2025
Juliet Gallagher
A real-world study comparing treatment patterns, health care resource utilization, and costs in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) found that chimeric antigen receptor T-cell (CAR T) therapy was associated with...
A real-world study comparing treatment patterns, health care resource utilization, and costs in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) found that chimeric antigen receptor T-cell (CAR T) therapy was associated with...
A real-world study comparing...
03/04/2025
Journal of Clinical Pathways
News
Cyclin D1 Quantification May Improve Prognostic Assessment in Mantle Cell Lymphoma
02/21/2025
Lisa Kuhns, PhD, MD
Higher Cyclin D1 protein levels detected through a novel quantification method correlate with better survival outcomes in patients with mantle cell lymphoma (MCL), highlighting its prognostic ability, according to a study published in...
Higher Cyclin D1 protein levels detected through a novel quantification method correlate with better survival outcomes in patients with mantle cell lymphoma (MCL), highlighting its prognostic ability, according to a study published in...
Higher Cyclin D1 protein levels...
02/21/2025
Journal of Clinical Pathways
News
Study Finds No Added Benefit of Auto-HCT for MCL Patients in Deep Remission
02/12/2025
Lisa Kuhns, PhD, MD
Consolidative autologous hematopoietic cell transplant (auto-HCT) provides no additional benefit for patients with mantle cell lymphoma (MCL) achieving undetectable minimal residual disease (uMRD6) in their first complete remission (CR),...
Consolidative autologous hematopoietic cell transplant (auto-HCT) provides no additional benefit for patients with mantle cell lymphoma (MCL) achieving undetectable minimal residual disease (uMRD6) in their first complete remission (CR),...
Consolidative autologous...
02/12/2025
Journal of Clinical Pathways

Expert Insights

Eliza A Hawkes, MD
Videos
Promising Advances in the Mantle Cell Lymphoma Treatment Landscape
02/13/2024
Eliza A. Hawkes, MD
Eliza A Hawkes, MD, shares some of the rapidly evolving treatment approaches for mantle cell lymphoma, including chemotherapy-free options and assessing responses through measurable residual disease technologies.
Eliza A Hawkes, MD, shares some of the rapidly evolving treatment approaches for mantle cell lymphoma, including chemotherapy-free options and assessing responses through measurable residual disease technologies.
Eliza A Hawkes, MD, shares some...
02/13/2024
Oncology
Bijal Shah, MD
Conference Coverage
Recent Breakthroughs in the Mantle Cell Lymphoma Treatment Landscape
01/08/2024
Bijal D. Shah, MD
Bijal D. Shah, MD, shares the breakthroughs in the mantle cell lymphoma treatment landscape that he found most promising at the 65th American Society of Hematology (ASH) Annual Meeting.
Bijal D. Shah, MD, shares the breakthroughs in the mantle cell lymphoma treatment landscape that he found most promising at the 65th American Society of Hematology (ASH) Annual Meeting.
Bijal D. Shah, MD, shares the...
01/08/2024
Oncology
Mengyang Di, MD, PhD
Videos
Real-World BTK Inhibitor Utilization and Outcomes Following Discontinuation in Older Patients With MCL
12/14/2022
Mengyang Di, MD, PhD, discussed a population-based analysis on real-world practice patterns and outcomes following Bruton Tyrosine Kinase Inhibitors in older patients with MCL at the ASH Annual Meeting.
Mengyang Di, MD, PhD, discussed a population-based analysis on real-world practice patterns and outcomes following Bruton Tyrosine Kinase Inhibitors in older patients with MCL at the ASH Annual Meeting.
Mengyang Di, MD, PhD, discussed...
12/14/2022
Journal of Clinical Pathways
Tycel Phillips, MD
Videos
Frontline Therapies for Patients With Untreated and Relapsed Mantle Cell Lymphoma
09/14/2022
Tycel Phillips, MD, reviews standard therapies utilized for patients with mantle cell lymphoma, including nonaggressive regimens and BTK inhibitor therapies.
Tycel Phillips, MD, reviews standard therapies utilized for patients with mantle cell lymphoma, including nonaggressive regimens and BTK inhibitor therapies.
Tycel Phillips, MD, reviews...
09/14/2022
Journal of Clinical Pathways
Mayur Narkhede, MD
Videos
Real-World Treatment Patterns and Outcomes Among Patients With Mantle Cell Lymphoma
07/21/2022
Mayur Narkhede, MD, analyzed treatment patterns among patients with mantle cell lymphoma at different lines of therapy, focusing on BTKi use, and compared outcomes with known prognostic factors.
Mayur Narkhede, MD, analyzed treatment patterns among patients with mantle cell lymphoma at different lines of therapy, focusing on BTKi use, and compared outcomes with known prognostic factors.
Mayur Narkhede, MD, analyzed...
07/21/2022
Journal of Clinical Pathways
ENGAGING EXPERTS
Real-World Practice Patterns and Predictors of Survival in Older Patients With MCL
01/15/2021
David Bond, MD, discusses results from a real-world study highlighting risk factors, clinical outcomes, andpredictors of survival in older patients with MCL treated in the rituximab era.
David Bond, MD, discusses results from a real-world study highlighting risk factors, clinical outcomes, andpredictors of survival in older patients with MCL treated in the rituximab era.
David Bond, MD, discusses...
01/15/2021
Journal of Clinical Pathways
ENGAGING EXPERTS
Novel BTK Inhibitor Promising for Mantle Cell Lymphoma
06/23/2020
Peter Martin, MD, Weill Cornell Medicine, New York, New York, discusses the data that led to the recent accelerated approval of zanubrutinib for the treatment of patients with mantle cell lymphoma.
Peter Martin, MD, Weill Cornell Medicine, New York, New York, discusses the data that led to the recent accelerated approval of zanubrutinib for the treatment of patients with mantle cell lymphoma.
Peter Martin, MD, Weill Cornell...
06/23/2020
Journal of Clinical Pathways
Headshot of Joe DePinto
Interview
Expanding Cell and Gene Therapy Adoption in Oncology Care
11/03/2026
Joe DePinto
In this interview, Joe DePinto discusses the growing adoption of cell and gene therapy in oncology care, focusing on tools and challenges providers, payers, and policymakers should be aware of when working to expand utilization among cancer...
In this interview, Joe DePinto discusses the growing adoption of cell and gene therapy in oncology care, focusing on tools and challenges providers, payers, and policymakers should be aware of when working to expand utilization among cancer...
In this interview, Joe DePinto...
11/03/2026
Journal of Clinical Pathways
Headshot of Dr Basu Roy
Interview
Improving Therapy Options and Patient Experiences in NSCLC: Part 2
10/21/2026
Upal Basu Roy, PhD, MPH
In this interview, Upal Basu Roy, PhD, MPH, discusses current challenges in treating non–small cell lung cancer (NSCLC) and explains how clinical pathways should evolve to focus on patient needs and experiences.
In this interview, Upal Basu Roy, PhD, MPH, discusses current challenges in treating non–small cell lung cancer (NSCLC) and explains how clinical pathways should evolve to focus on patient needs and experiences.
In this interview, Upal Basu...
10/21/2026
Journal of Clinical Pathways
Rob Helton
Interview
Embedding Genomic Data, Clinical Guidelines, and Payer Requirements Into Community Oncology Workflows
10/19/2026
Rob Helton, DPT
Rob Helton explores how intelligent medical records and integrated clinical decision support can streamline community oncology workflows, improve clinical pathway adherence, and reduce barriers to precision medicine.
Rob Helton explores how intelligent medical records and integrated clinical decision support can streamline community oncology workflows, improve clinical pathway adherence, and reduce barriers to precision medicine.
Rob Helton explores how...
10/19/2026
Journal of Clinical Pathways
Headshot of Dr Basu Roy
Interview
Improving Therapy Options and Patient Experiences in NSCLC: Part 1
10/13/2026
Upal Basu Roy, PhD, MPH
In this interview, Upal Basu Roy, PhD, MPH, discusses improvements in the treatment landscape of non–small cell lung cancer (NSCLC) as well as ongoing research aimed at further enhancing disease management.
In this interview, Upal Basu Roy, PhD, MPH, discusses improvements in the treatment landscape of non–small cell lung cancer (NSCLC) as well as ongoing research aimed at further enhancing disease management.
In this interview, Upal Basu...
10/13/2026
Journal of Clinical Pathways
Gary Simmons, DO, MSHA
Interview
Expanding CAR T-Cell Therapy Access in Community Oncology
09/29/2026
Gary L. Simmons, DO
Gary L. Simmons, DO, MSHA, discusses Virginia Oncology Associates’ experience delivering CAR T-cell therapy in the community and how community-based programs can expand patient access while supporting safe delivery, care coordination, and...
Gary L. Simmons, DO, MSHA, discusses Virginia Oncology Associates’ experience delivering CAR T-cell therapy in the community and how community-based programs can expand patient access while supporting safe delivery, care coordination, and...
Gary L. Simmons, DO, MSHA,...
09/29/2026
Journal of Clinical Pathways
Nikki Martin Headshot
Interview
Adopting Reflex Biomarker Testing to Improve Clinical Workflows for Patients With Non–Small Cell Lung Cancer
09/18/2026
Nikki Martin, MA
In this interview, Nikki Martin, MA, discusses the benefits of comprehensive biomarker testing for patients with newly diagnosed non–small cell lung cancer (NSCLC), explaining how it can streamline decision-making processes, improve clinical...
In this interview, Nikki Martin, MA, discusses the benefits of comprehensive biomarker testing for patients with newly diagnosed non–small cell lung cancer (NSCLC), explaining how it can streamline decision-making processes, improve clinical...
In this interview, Nikki Martin,...
09/18/2026
Journal of Clinical Pathways
Kelsey Pan Headshot
Interview
Navigating Biomarker-Driven Treatment in Advanced NSCLC: Part II
08/18/2026
Kelsey Pan, MD
A guest expert discusses evolving approaches to managing treatment resistance in non-small cell lung cancer, barriers to equitable precision oncology, and emerging targeted therapies that may shape future treatment strategies.
A guest expert discusses evolving approaches to managing treatment resistance in non-small cell lung cancer, barriers to equitable precision oncology, and emerging targeted therapies that may shape future treatment strategies.
A guest expert discusses...
08/18/2026
Journal of Clinical Pathways
Kelsey Pan Headshot
Interview
Navigating Biomarker-Driven Treatment in Advanced NSCLC: Part I
08/18/2026
Kelsey Pan, MD
In this interview, Kelsey Pan, MD, MPH, discusses how biomarker testing and emerging targeted therapies are reshaping treatment selection, resistance management, and precision oncology in advanced non–small cell lung cancer (NSCLC).
In this interview, Kelsey Pan, MD, MPH, discusses how biomarker testing and emerging targeted therapies are reshaping treatment selection, resistance management, and precision oncology in advanced non–small cell lung cancer (NSCLC).
In this interview, Kelsey Pan,...
08/18/2026
Journal of Clinical Pathways
Deirdre Saulet, PhD
Blog
How AI, Data, and Real-World Evidence Are Transforming Oncology Clinical Pathways
07/14/2026
Deirdre Saulet, PhD
Clinical Pathways Congress 2026 will bring together oncology leaders to explore practical strategies for using technology to build smarter, more responsive clinical pathways that improve care delivery.
Clinical Pathways Congress 2026 will bring together oncology leaders to explore practical strategies for using technology to build smarter, more responsive clinical pathways that improve care delivery.
Clinical Pathways Congress 2026...
07/14/2026
Journal of Clinical Pathways
B-cell lymphoma
Videos
Dual-Targeting CAR T-Cell Therapy: Implications for Relapsed or Refractory Large B-Cell Lymphoma
07/06/2026
Paolo Strati, MD
Paolo Strati, MD, discusses how findings from the ZUMA-14 trial could shape the future of dual-targeting CAR T-cell therapy, treatment sequencing, and minimal residual disease monitoring in relapsed or refractory large B-cell lymphoma.
Paolo Strati, MD, discusses how findings from the ZUMA-14 trial could shape the future of dual-targeting CAR T-cell therapy, treatment sequencing, and minimal residual disease monitoring in relapsed or refractory large B-cell lymphoma.
Paolo Strati, MD, discusses how...
07/06/2026
Journal of Clinical Pathways

Newsfeed

News
Study Shows Improved Outcomes in Older Adults With Mantle Cell Lymphoma Following Adoption of New Therapies
06/16/2025
Juliet Gallagher
New findings from a large, retrospective cohort study using SEER-Medicare data highlight improvements in survival outcomes over time among older adults with mantle cell lymphoma (MCL), likely associated with the adoption of novel therapeutic...
New findings from a large, retrospective cohort study using SEER-Medicare data highlight improvements in survival outcomes over time among older adults with mantle cell lymphoma (MCL), likely associated with the adoption of novel therapeutic...
New findings from a large,...
06/16/2025
Journal of Clinical Pathways
News
Ibrutinib Plus Venetoclax Improves Outcomes in Relapsed Mantle Cell Lymphoma: SYMPATICO Trial
06/11/2025
Grace Taylor, MS, MA
Findings from the SYMPATICO trial show that combining ibrutinib with venetoclax significantly prolongs progression-free survival in relapsed mantle cell lymphoma.
Findings from the SYMPATICO trial show that combining ibrutinib with venetoclax significantly prolongs progression-free survival in relapsed mantle cell lymphoma.
Findings from the SYMPATICO...
06/11/2025
Journal of Clinical Pathways
News
Safety and Tolerability of Second Generation BTK Inhibitors in Relapsed Mantle Cell Lymphoma
05/14/2025
Grace Taylor, MS, MA
Real-world findings support the tolerability of acalabrutinib and zanubrutinib in mantle cell lymphoma, highlighting their safety advantage over ibrutinib.
Real-world findings support the tolerability of acalabrutinib and zanubrutinib in mantle cell lymphoma, highlighting their safety advantage over ibrutinib.
Real-world findings support the...
05/14/2025
Journal of Clinical Pathways
News
Study Shows Promising Safety and Efficacy of ABR Combination in Mantle Cell Lymphoma
05/07/2025
Grace Taylor, MS, MA
The combination therapy of acalabrutinib, bendamustine, and rituximab shows promise in a recent study for mantle cell lymphoma.
The combination therapy of acalabrutinib, bendamustine, and rituximab shows promise in a recent study for mantle cell lymphoma.
The combination therapy of...
05/07/2025
Journal of Clinical Pathways
News
New Risk Model Enhances Prognostic Precision in Mantle Cell Lymphoma
04/10/2025
Danielle Sposato
A large retrospective study published in Scientific Reports involving 979 patients from 9 cancer centers has introduced a powerful new prognostic tool for mantle cell lymphoma (MCL), a rare and aggressive form of non-Hodgkin lymphoma.
A large retrospective study published in Scientific Reports involving 979 patients from 9 cancer centers has introduced a powerful new prognostic tool for mantle cell lymphoma (MCL), a rare and aggressive form of non-Hodgkin lymphoma.
A large retrospective study...
04/10/2025
Journal of Clinical Pathways
News
Survival in Mantle Cell Lymphoma Improves With Shifts in Treatment Patterns
04/07/2025
Hannah Musick
A study of older MCL patients found significant survival gains linked to increased first-line use of rituximab-bendamustine (BR) and Bruton tyrosine kinase inhibitors (BTKis), but more modest improvements after second-line therapy.
A study of older MCL patients found significant survival gains linked to increased first-line use of rituximab-bendamustine (BR) and Bruton tyrosine kinase inhibitors (BTKis), but more modest improvements after second-line therapy.
A study of older MCL patients...
04/07/2025
Journal of Clinical Pathways
News
Academic Cancer Centers Improve Outcomes for Patients With Mantle Cell Lymphoma
03/18/2025
Lisa Kuhns, PhD, MD
Patients with mantle cell lymphoma (MCL) who receive treatment at academic cancer centers experience longer overall survival and higher participation in clinical trials compared to those treated in community-based practices, according to a...
Patients with mantle cell lymphoma (MCL) who receive treatment at academic cancer centers experience longer overall survival and higher participation in clinical trials compared to those treated in community-based practices, according to a...
Patients with mantle cell...
03/18/2025
Journal of Clinical Pathways
News
Early Measurable Residual Disease Assessment Predicts Survival in Patients With Mantle Cell Lymphoma
03/12/2025
Lisa Kuhns, PhD, MD
Patients with mantle cell lymphoma (MCL) can benefit from measurable residual disease (MRD) assessment during induction therapy, with the timing and kinetics of MRD negativity significantly impacting prognosis and treatment strategies,...
Patients with mantle cell lymphoma (MCL) can benefit from measurable residual disease (MRD) assessment during induction therapy, with the timing and kinetics of MRD negativity significantly impacting prognosis and treatment strategies,...
Patients with mantle cell...
03/12/2025
Journal of Clinical Pathways
News
CAR T-Cell Therapy Cuts Costs and Improves Treatment-Free Intervals
03/04/2025
Juliet Gallagher
A real-world study comparing treatment patterns, health care resource utilization, and costs in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) found that chimeric antigen receptor T-cell (CAR T) therapy was associated with...
A real-world study comparing treatment patterns, health care resource utilization, and costs in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) found that chimeric antigen receptor T-cell (CAR T) therapy was associated with...
A real-world study comparing...
03/04/2025
Journal of Clinical Pathways
News
Cyclin D1 Quantification May Improve Prognostic Assessment in Mantle Cell Lymphoma
02/21/2025
Lisa Kuhns, PhD, MD
Higher Cyclin D1 protein levels detected through a novel quantification method correlate with better survival outcomes in patients with mantle cell lymphoma (MCL), highlighting its prognostic ability, according to a study published in...
Higher Cyclin D1 protein levels detected through a novel quantification method correlate with better survival outcomes in patients with mantle cell lymphoma (MCL), highlighting its prognostic ability, according to a study published in...
Higher Cyclin D1 protein levels...
02/21/2025
Journal of Clinical Pathways
News
Insurance Restrictions and High Costs Limit Blood Cancer Treatment Access
10/14/2026
Grace Taylor, MS, MA
A nationwide study found that insurance restrictions and high out-of-pocket costs prevent many patients with blood cancers from filling prescribed oral anticancer medications, even after insurer approval.
A nationwide study found that insurance restrictions and high out-of-pocket costs prevent many patients with blood cancers from filling prescribed oral anticancer medications, even after insurer approval.
A nationwide study found that...
10/14/2026
Journal of Clinical Pathways
News
EOM Lung Patient Pilot Associated With Reduced Emergency Care Utilization
10/09/2026
Rebecca Amrick
In the Enhancing Oncology Model (EOM) Lung Patient Pilot program, nurse outreach was associated with reduced emergency care utilization and health care spending among patients with metastatic lung cancer.
In the Enhancing Oncology Model (EOM) Lung Patient Pilot program, nurse outreach was associated with reduced emergency care utilization and health care spending among patients with metastatic lung cancer.
In the Enhancing Oncology Model...
10/09/2026
Journal of Clinical Pathways
News
MYLUNG Study Links Timely Biomarker Testing to Improved Outcomes in mNSCLC
09/29/2026
Rebecca Amrick
Protocol 2 of the MYLUNG study found that improvements in biomarker testing rates increased rates of targeted first-line therapies among patients with metastatic non–small cell lung cancer (mNSCLC), illustrating how biomarker testing can...
Protocol 2 of the MYLUNG study found that improvements in biomarker testing rates increased rates of targeted first-line therapies among patients with metastatic non–small cell lung cancer (mNSCLC), illustrating how biomarker testing can...
Protocol 2 of the MYLUNG study...
09/29/2026
Journal of Clinical Pathways
News
Comprehensive Molecular Profiling Linked to Improved Survival in NSCLC
09/28/2026
Grace Taylor, MS, MA
A study found that comprehensive molecular profiling was associated with improved survival and reduced health care utilization among patients with non–small cell lung cancer (NSCLC), yet fewer than 1 in 15 patients underwent testing.
A study found that comprehensive molecular profiling was associated with improved survival and reduced health care utilization among patients with non–small cell lung cancer (NSCLC), yet fewer than 1 in 15 patients underwent testing.
A study found that comprehensive...
09/28/2026
Journal of Clinical Pathways
Conference Coverage
Innovations in Relapsed or Refractory Multiple Myeloma Management
09/21/2026
Rebecca Amrick
At the National Comprehensive Cancer Network 2026 Annual Congress: Hematologic Malignancies, panelists discussed innovations in treating relapsed or refractory multiple myeloma and strategies to improve disease management.
At the National Comprehensive Cancer Network 2026 Annual Congress: Hematologic Malignancies, panelists discussed innovations in treating relapsed or refractory multiple myeloma and strategies to improve disease management.
At the National Comprehensive...
09/21/2026
Journal of Clinical Pathways
Conference Coverage
Managing Treatment Toxicity Among Patients With Chronic Myeloid Lymphoma
09/21/2026
Rebecca Amrick
Jenna Moran, MSN, FNP-BC, outlined strategies for managing tyrosine kinase inhibitor–related toxicities in patients with chronic myeloid leukemia during a session at the National Comprehensive Cancer Network 2026 Annual Congress.
Jenna Moran, MSN, FNP-BC, outlined strategies for managing tyrosine kinase inhibitor–related toxicities in patients with chronic myeloid leukemia during a session at the National Comprehensive Cancer Network 2026 Annual Congress.
Jenna Moran, MSN, FNP-BC,...
09/21/2026
Journal of Clinical Pathways
Conference Coverage
De-Escalating TKI Therapy Based on Risk and Response for Patients With CML
09/18/2026
Rebecca Amrick
At the National Comprehensive Cancer Network 2026 Annual Congress: Hematologic Malignancies, Vivian G. Oehler, MD, shared insights on de-escalating tyrosine kinase inhibitor (TKI) therapy among patients with chronic myeloid leukemia (CML)...
At the National Comprehensive Cancer Network 2026 Annual Congress: Hematologic Malignancies, Vivian G. Oehler, MD, shared insights on de-escalating tyrosine kinase inhibitor (TKI) therapy among patients with chronic myeloid leukemia (CML)...
At the National Comprehensive...
09/18/2026
Journal of Clinical Pathways
News
Anemia Associated With Higher Mortality and AML Transformation Risk in Myelofibrosis
09/17/2026
Rebecca Amrick
Researchers found that the presence of anemia is likely to increase the risk of mortality and acute myeloid leukemia (AML) transformation among patients with myelofibrosis, indicating anemia as a potential prognostic marker.
Researchers found that the presence of anemia is likely to increase the risk of mortality and acute myeloid leukemia (AML) transformation among patients with myelofibrosis, indicating anemia as a potential prognostic marker.
Researchers found that the...
09/17/2026
Journal of Clinical Pathways
News
Enhanced Financial Assistance Associated With Improved Radiotherapy Completion
09/08/2026
Rebecca Amrick
Researchers found that providing financial assistance for cancer patients with unmet social needs was associated with improvements in radiotherapy completion, indicating a potential strategy to promote health equity and reduce care gaps.
Researchers found that providing financial assistance for cancer patients with unmet social needs was associated with improvements in radiotherapy completion, indicating a potential strategy to promote health equity and reduce care gaps.
Researchers found that providing...
09/08/2026
Journal of Clinical Pathways
News
Molecular Testing Improves Survival Outcomes for Patients With Endometrial Cancer, Study Finds
09/03/2026
Rebecca Amrick
Researchers found that testing for molecular biomarkers in patients with endometrial cancer is associated with prolonged survival and lower incremental costs than no testing, illustrating the importance of molecular classification in...
Researchers found that testing for molecular biomarkers in patients with endometrial cancer is associated with prolonged survival and lower incremental costs than no testing, illustrating the importance of molecular classification in...
Researchers found that testing...
09/03/2026
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Survival Outcomes in Patients With MCL Treated With Bruton Tyrosine Kinase Inhibitors
04/12/2022
True or False: BTK inhibitors in the second-line setting improve overall survival and lymphoma-specific survival among patients with MCL.
True or False: BTK inhibitors in the second-line setting improve overall survival and lymphoma-specific survival among patients with MCL.
True or False: BTK inhibitors in...
04/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Treatment Patterns for MCL
01/20/2022
True or False: Bendamustine plus rituximab is the most commonly used first-line treatment for MCL in the US, while receipt of stem cell transplant is uncommon.
True or False: Bendamustine plus rituximab is the most commonly used first-line treatment for MCL in the US, while receipt of stem cell transplant is uncommon.
True or False: Bendamustine plus...
01/20/2022
Journal of Clinical Pathways
Quiz
Quiz: Rituximab Among Older Patients With MCL
09/03/2021
True or False: Older patients with MCL may not benefit from maintenance rituximab, due to an inability to tolerate this treatment.
True or False: Older patients with MCL may not benefit from maintenance rituximab, due to an inability to tolerate this treatment.
True or False: Older patients...
09/03/2021
Journal of Clinical Pathways
Quiz
Quiz: Impact of Comorbidities on Treatment Choices for Older Patients With MCL
04/28/2021
04/28/2021
Journal of Clinical Pathways
Quiz
Quiz: Is KTE-X19 a Cost-Effective Treatment for MCL?
04/23/2021
04/23/2021
Journal of Clinical Pathways
Quiz
Quiz: MRD Status for Patients With MCL
03/08/2021
03/08/2021
Journal of Clinical Pathways
Quiz
Regional Inequalities Persist in Lung Cancer Mortality Trends
11/19/2025
11/19/2025
Journal of Clinical Pathways
Quiz
Rural Health Transformation Program Fund Distribution
09/29/2025
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health...
09/29/2025
Journal of Clinical Pathways
Quiz
Uncovering the True Cost of Care
09/18/2025
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable...
09/18/2025
Journal of Clinical Pathways
Quiz
Understanding the NCCN Guidelines Navigator
08/27/2025
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive...
08/27/2025
Journal of Clinical Pathways
Quiz
Specialty Palliative Care Trends for Medicare Beneficiaries
08/12/2025
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of...
08/12/2025
Journal of Clinical Pathways
Quiz
Understanding the Role of Clinical Pathways in Oncology Care
07/30/2025
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical...
07/30/2025
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways

Special Reports

Special Report
Advancing a Standardized Economic Framework to Power Oncology Pathways: Methods and Model Development From Phase II of the Predictable Cost of Care Working Group
04/23/2026
Edward Arrowsmith, MD; Alan J. Balch, PhD, MSc; Vishnukamal Golla, MD, MPH; Andrew Hertler, MD, FACP; David Jackman, MD; Olaf Lodbrok, MS, MBA; Lalan Wilfong, MD; Gordon Kuntz; Carole Tremonti, RN, MBA
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and...
04/23/2026
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use